/PRNewswire/ Amid repeated failures of drug trials for Alzheimer s disease, a small pilot study using a precision medicine approach has reported the first.
Trial First to Show Improvements in Alzheimer s Patients
News provided by
Share this article
Share this article
BURLINGAME, Calif., May 13, 2021 /PRNewswire/ Pharmaceutical trials for Alzheimer s have failed repeatedly, but a new study, using a fundamentally different approach, has provided the first success: using precision medicine to identify and target the drivers of Alzheimer s or pre-Alzheimer s in each patient, a team of physicians and researchers has posted exciting, positive results in medRxiv, the Yale-backed site for health sciences.
(PRNewsfoto/Apollo Health)
(PRNewsfoto/Apollo Health)
Until now, therapeutic development for Alzheimer s disease has been almost uniformly unsuccessful, with over 400 failed clinical trials. The few successes (e.g., memantine) have not offered sustained improvement. For example, the recent claim of a positive trial for the drug candidate donanemab did not show cognitive improvement, nor even stabilization of dementia, but merely red
RSS Feeds:
A New Anti-Aging Agent is Making Its Way Into Skincare, and the Results Are on Par with Many Cosmetic Procedures New Orleans, LA, May 07, 2021 (PR.com) Topical NAD+ products, previously available by prescription, are exploding onto the aesthetic scene. In 2020, Avior Nutritionals, the makers of Real NAD+, released a nonprescription skincare product that boasts more than twice the amount of NAD+ as its prescription predecessor.
Avior’s skincare line is called NADIA and its flagship product is a serum that is applied to the face. Kat Toups, MD, a functional medicine physician located in Walnut Creek, CA said of the serum, “The increased NAD strength (compared with prescription NAD Face Paste) translates into even more benefits for my skin.” Toups went on to call NADIA Power Serum “the anti-aging bomb!”